Clinical efficacy of combination therapy with Butylphthalide and fibrinolytic enzyme for acute cerebral infarction

Abstract

Objective To evaluate the clinical efficacy of Butylphthalide combined with fibrinolytic enzyme in the treatment of acute cerebral infarction. Methods A total of 60 elderly patients with acute cerebral infarction who had missed the opportunity of thrombolytic therapy were enrolled in this study from January 2014 to December 2016 at Zhengzhou University Second Affiliated Hospital.Patients were randomly divided into an observation group(n=30)and a control group(n=30). Patients in the control group were treated with fibrinolytic enzyme alone, and those in the observation group received Butylphthalide combined with fibrinolytic enzyme.Peak flow velocity and mean flow velocity of the middle cerebral artery were analyzed and compared between the two groups before and after treatment.Data on clinical safety, efficacy, the national institutes of health stroke scale(NIHSS)and the Barthel score were also compared between the two groups. Results After treatment, the peak velocity 〔(74.60±4.31)cm/s vs.(69.19±3.36)cm/s〕 and average velocity 〔(38.71±2.29)cm/s vs.(34.01±2.01)cm/s〕 of the middle cerebral artery were significantly increased in the treatment group compared with those in the observation group(both P<0.05). Meanwhile, the clinical efficacy was significantly higher in the observation group(96.7% vs.73.3%, P<0.05). Moreover, NIHSS scores 〔(5.91±3.51)vs.(8.31±3.09)〕and Barthel scores 〔(71.29±3.81)vs.(53.60±4.33)〕 were significantly improved in the treatment group compared with those in the observation group(both P<0.05). In addition, there were no obvious adverse reactions during treatment in the two groups. Conclusions Butylphthalide combined with plasmin can safely and effectively improve cerebral hemodynamics and prognosis in patients with acute cerebral infarction. Key words: Brain infarction; Plasmin